BR112013015877A2 - composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica. - Google Patents

composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.

Info

Publication number: BR112013015877A2
Authority: BR; Brazil
Prior art keywords: amelioration; compound; treatment; prophylaxis; diseases
Prior art date: 2010-12-22

Application number

BR112013015877A

Other languages

English (en)

Inventor

Grue- S\Orensen Gunnar

Högberg Thomas

Liang Xifu

Original Assignee

Leo Laboratories Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-22

Filing date

2011-12-22

Publication date

2018-06-05

2011-12-22 Application filed by Leo Laboratories Ltd filed Critical Leo Laboratories Ltd

2018-06-05 Publication of BR112013015877A2 publication Critical patent/BR112013015877A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/56—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/44—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups being part of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/013—Esters of alcohols having the esterified hydroxy group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
- C07C69/24—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with monohydroxylic compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
- C07C69/54—Acrylic acid esters; Methacrylic acid esters
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/593—Dicarboxylic acid esters having only one carbon-to-carbon double bond
- C07C69/60—Maleic acid esters; Fumaric acid esters
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/608—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a ring other than a six-membered aromatic ring in the acid moiety
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
- C07C69/614—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety of phenylacetic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
- C07C69/616—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety polycyclic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
- C07C69/618—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety having unsaturation outside the six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/86—Ring systems containing bridged rings containing four rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BR112013015877A 2010-12-22 2011-12-22 composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica. BR112013015877A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201061426365P	2010-12-22	2010-12-22
PCT/EP2011/073759 WO2012085189A1 (en)	2010-12-22	2011-12-22	Ingenol-3-acylates i

Publications (1)

Publication Number	Publication Date
BR112013015877A2 true BR112013015877A2 (pt)	2018-06-05

Family

ID=45464538

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112013015877A BR112013015877A2 (pt)	2010-12-22	2011-12-22	composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.

Country Status (8)

Country	Link
US (1)	US9388124B2 (pt)
EP (1)	EP2655311A1 (pt)
JP (1)	JP2014507396A (pt)
CN (1)	CN103443066A (pt)
AU (1)	AU2011347261A1 (pt)
BR (1)	BR112013015877A2 (pt)
CA (1)	CA2822360A1 (pt)
WO (1)	WO2012085189A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2014015497A (es)	2012-06-26	2015-03-06	Leo Lab Ltd	3-o-heteroaril-ingenol.
BR102012028120B8 (pt) *	2012-11-01	2022-08-02	Amazonia Fitomedicamentos Ltda	Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
CN103936590B (zh) *	2014-05-05	2016-02-24	中国科学院昆明植物研究所	大戟属中的二萜类化合物及其药物组合物和其在制药中的应用
WO2016191835A1 (pt) *	2015-06-03	2016-12-08	Amazônia Fitomedicamentos Ltda.	Método de preparação de ingenol-5,20-acetonida, método de preparação de 3-etinil-3-hidroxi-4.7.7-trimetilbiciclo[4.1.0] heptano-2-carbaldeído, método de preparação do composto 2,2-dimetil-4-etinil-5 -trifenilfosforanilideno-1,3-dioxano e composto intermediário
WO2016191836A1 (pt) *	2015-06-03	2016-12-08	Amazônia Fitomedicamentos Ltda.	Método de preparação de ingenol-3-dodecanoato, método de preparação de 3-etinil-3-hidroxi-4.7.7-trimetilbiciclo[4.1.0]heptano-2-carbaldeído e método de preparação de 2,2-dimetil-4-etinil-5-trifenilfosforanilideno-1,3-dioxano
WO2016191837A1 (pt) *	2015-06-03	2016-12-08	Amazônia Fitomedicamentos Ltda.	Método de preparação de ingenol-3-hexanoato, método de preparação de 3-etinil-3-hidroxi-4.7.7-trimetilbiciclo[4.1.0]heptano-2-carbaldeído e método de preparação do composto 2,2-dimetil-4-etinil-5-trifenilfosforanilideno-1,3-dioxano
US10583140B2 (en)	2016-01-27	2020-03-10	Glaxosmithkline Intellectual Property Development Limited	Ingenol analogs, pharmaceutical compositions and methods of use thereof
WO2017156350A1 (en)	2016-03-09	2017-09-14	K-Gen, Inc.	Methods of cancer treatment
CN114940667B (zh) *	2022-04-28	2023-06-13	宁波大学	一种二萜类化合物及其制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2902506A1 (de) *	1979-01-23	1980-07-24	Deutsches Krebsforsch	Verwendung von nicht oder nur gering irritierenden und/oder promovierenden diterpenalkoholen und von derivaten davon als antineoplastische mittel
JPH07165600A (ja)	1993-10-18	1995-06-27	Souyaku Gijutsu Kenkyusho:Kk	抗ウイルス剤
JPH08245505A (ja)	1994-09-09	1996-09-24	Tosoh Corp	ジテルペン誘導体、その製造法及びそれを有効成分として含有する抗腫瘍剤
AUPO864097A0 (en)	1997-08-19	1997-09-11	Peplin Pty Ltd	Anti-cancer compounds
AUPQ801700A0 (en)	2000-06-07	2000-06-29	Peplin Research Pty Ltd	Enzyme and viral activation
AUPQ923100A0 (en) *	2000-08-07	2000-08-31	Peplin Research Pty Ltd	Treatment of prostate cancer
JP2003171349A (ja)	2001-08-06	2003-06-20	Univ Nihon	新規なジテルペン類、及びこれを用いた組成物、抗炎症剤、抗癌剤
DK1628673T3 (da)	2004-01-01	2007-06-18	Panacea Biotec Ltd	Farmaceutiske sammensætninger, der omfatter en ekstrakt af Euphorbia prostrata
US8106092B2 (en) *	2004-12-13	2012-01-31	Leo Laboratories Limited	Treatment of solid cancers
WO2006116897A1 (fr)	2005-04-30	2006-11-09	Nihon University	Diterpenes provenant de euphorbia kansui et leur utilisation
EP1951221A1 (en) *	2005-11-14	2008-08-06	Peplin Research Pty Ltd.	Use of angeloyl-substituted ingenanes in combination with other agents to treat cancer
WO2007059584A1 (en)	2005-11-25	2007-05-31	Peplin Research Pty Ltd	Methods for wound healing
GB0525680D0 (en) *	2005-12-16	2006-01-25	Peplin Ltd	Therapeutic compositions
AU2006201661A1 (en)	2006-04-20	2007-11-08	Peplin Research Pty Ltd	A method of diagnosis and treatment
CA2541903A1 (en) *	2006-04-20	2007-10-20	Peplin Research Pty. Ltd.	A method of diagnosis and treatment
ES2564173T3 (es) *	2007-04-30	2016-03-18	Leo Laboratories Limited	Tratamiento de lesiones inducidas por virus
JP2010526824A (ja)	2007-05-11	2010-08-05	ソネボーンインコーポレイテッド	シリコーン類似の特性を有するワセリン
AU2010200429A1 (en)	2009-02-05	2010-08-19	Ecobiotics Ltd	Method of reducing or preventing blowfly strike
EP2395993B1 (en)	2009-02-13	2017-06-21	Leo Laboratories Limited	Skin treatment
WO2012010172A1 (en)	2010-07-20	2012-01-26	Leo Pharma A/S	A method of producing ingenol-3-angelate

2011
- 2011-12-22 JP JP2013545399A patent/JP2014507396A/ja active Pending
- 2011-12-22 WO PCT/EP2011/073759 patent/WO2012085189A1/en active Application Filing
- 2011-12-22 BR BR112013015877A patent/BR112013015877A2/pt not_active IP Right Cessation
- 2011-12-22 AU AU2011347261A patent/AU2011347261A1/en not_active Abandoned
- 2011-12-22 EP EP11805841.1A patent/EP2655311A1/en not_active Ceased
- 2011-12-22 CA CA2822360A patent/CA2822360A1/en not_active Abandoned
- 2011-12-22 US US13/996,549 patent/US9388124B2/en not_active Expired - Fee Related
- 2011-12-22 CN CN2011800681750A patent/CN103443066A/zh active Pending

Also Published As

Publication number	Publication date
CA2822360A1 (en)	2012-06-28
US20130324600A1 (en)	2013-12-05
RU2013133865A (ru)	2015-01-27
US9388124B2 (en)	2016-07-12
WO2012085189A1 (en)	2012-06-28
CN103443066A (zh)	2013-12-11
EP2655311A1 (en)	2013-10-30
AU2011347261A1 (en)	2013-07-11
JP2014507396A (ja)	2014-03-27

Publication	Publication Date	Title
BR112013015855A2 (pt)	2018-06-05	composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
BR112013015859A2 (pt)	2018-11-21	composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica
BR112013015877A2 (pt)	2018-06-05	composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
CL2013001654A1 (es)	2014-03-28	Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
EA201291336A1 (ru)	2013-04-30	Замещенные 5-фтор-1н-пиразолопиридины и их применение
BR112015003376A8 (pt)	2018-01-23	composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
BR112014010206A2 (pt)	2017-05-16	composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
SMT201600055B (it)	2016-04-29	Composizione farmaceutica per il trattamento o la prevenzione del glaucoma
BRPI1013705A2 (pt)	2016-04-05	compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
BR112014010177A2 (pt)	2017-04-25	composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
IL231536A (en)	2016-09-29	Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
WO2013169864A3 (en)	2014-01-03	TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
ZA201304638B (en)	2016-02-24	Composition for use in the prevention and /or treatment of skin condition and skin diseases.
BRPI1009324A2 (pt)	2015-11-24	compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
EA201390060A1 (ru)	2013-07-30	Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
WO2011088120A8 (en)	2012-09-13	Antibody formulation and therapeutic regimens
CL2013003372A1 (es)	2014-07-25	Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
BR112013011968A2 (pt)	2016-08-30	composição farmacêutica, métodos de tratamento e usos da mesma
HK1202415A1 (en)	2015-10-02	Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15- hetre and methods of use thereof dgla15-ohepa/ 15-hetre
BR112012002265A2 (pt)	2016-06-14	composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
BRPI1007092A2 (pt)	2015-08-18	"derivados de hidroxamato, uso dos derivados de hidroxamato, composições farmacêuticas, método para prevenção ou tratamento de doença e método de produção de derivados de hidroxamato"
WO2015015378A3 (en)	2015-05-14	Heterobicycloaryl rorc2 inhibitors and methods of use thereof
WO2011141488A3 (en)	2012-04-05	Pharmaceutical compositions comprising hydromorphone and naloxone
WO2012100043A3 (en)	2012-10-18	Controlled release oral pharmaceutical dosage forms comprising mgbg
GB2497453B8 (en)	2018-01-31	Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV

Legal Events

Date	Code	Title	Description
2018-06-12	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2018-10-23	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2475 DE 12-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.